ArticleScientific reports2026
Understanding indeterminate HIV serology through antigen-band pattern analysis of INNO-LIA and recomLine HIV confirmatory assays.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Indeterminate Human Immunodeficiency Virus (HIV) serological results remain a major challenge in confirmatory diagnosis, delaying reporting and clinical decision-making. The INNO-LIA HIV I/II Score assay, a widely used confirmatory line immunoassay, frequently produces indeterminate profiles that complicate interpretation. This study evaluated the Mikrogen recomLine HIV-1/2 IgG assay against INNO-LIA, incorporating HIV-1 RNA PCR as an adjudicative reference within the Architect-reactive samples, with emphasis on antigen-band patterns underlying indeterminate results. A total of 180 archived serum samples previously tested by the Architect HIV Ag/Ab Combo and INNO-LIA were retested using recomLine; 80 Architect-reactive samples underwent HIV-1 RNA PCR testing. When only definitive results were considered, recomLine demonstrated complete agreement with INNO-LIA. When indeterminate results were included as non-concordant, specificity was 98.3% (114/116). INNO-LIA produced more indeterminate results than recomLine (13.3% vs. 2.8%), mainly due to isolated gp41 reactivity. RecomLine reclassified 85% of INNO-LIA indeterminate samples, all of tested PCR-negative. These findings provide insights into mechanisms underlying indeterminate HIV serology, suggesting that incomplete or isolated antigenic responses, particularly gp41, are major contributors. No HIV-2 monoinfection or HIV-1/2 dual infections were identified. Overall, recomLine reduced indeterminate outcomes while maintaining high diagnostic accuracy, supporting its role as a confirmatory assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.